A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

New blinded preliminary BRTX-100 data described this past Saturday at prestigious "2025 Winners in Industry Innovations in MSK Health” presentation - - Among other positive preliminary data analyses, ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...